Connect with us

BUSINESS

Cell Separation Technologies Market Size, Share | Industry Report 2022-2027

Published

on

The latest research study, “Cell Separation Technologies Market Growth, Opportunity and Forecast 2022-2027” has been added by IMARC Group. The global cell separation technologies market size reached a value of US$ 7.62 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 19.28 Billion by 2027, exhibiting a CAGR of 16.10% during 2022-2027.

Cell Separation Technologies Market Overview :

Utilizing extracellular characteristics, cell separation technologies—also known as cell isolation or cell sorting—identify and extract one or more cells from the heterogeneous mixture. Immunomagnetic cell separation, fluorescence-activated cell sorting (FACS), density gradient centrifugation, immunogenicity cell isolation, and microfluidic cell sorting are a few of the methods for separating cells. These methods are used in accordance with the density, variety in size, shape, and expression of surface proteins of the cells. They are used in the healthcare industry to treat a variety of chronic illnesses, including cancer, AIDS, and cystic fibrosis.

Cell Separation Technologies Market Trends and Drivers:

The market is primarily driven by the rising adoption of cell separation technologies in the pharmaceutical industry to improve drug discovery methods and develop drugs with enhanced effectiveness.

In addition, cell separation technologies are gaining popularity due to the rising prevalence of chronic diseases, especially among the geriatric population. Besides this, extensive investments in research and development (R&D) activities in biotechnology for inventing and utilizing separated cells for developing cell-based treatments and therapies are creating a positive outlook for the market.

Other factors, such as the rapid expansion in the pharmaceutical and biotechnology industry, the increasing requirement for personalized medicines, several initiatives undertaken by governments to strengthen the healthcare infrastructure by enhancing cell-based technology, and an enhanced focus on cell-based research, are further propelling the market growth.

Request a Free PDF Sample for more detailed market insights: https://www.imarcgroup.com/cell-separation-technologies-market/requestsample

COVID-19 Impact Analysis

Note: We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.

Global Cell Separation Technologies Market 2022-2027 Analysis and Segmentation:

Competitive Landscape:

The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.

Akadeum Life Sciences, Alfa Laval AB, Becton, Dickinson and Company, Bio-Rad Laboratories Inc., Corning Incorporated, Merck KGaA, Miltenyi Biotec Inc., PerkinElmer Inc., pluriSelect Life Science UG (haftungsbeschränkt) & Co. KG, Stemcell Technologies Inc., Terumo Corporation and Thermo Fisher Scientific Inc.

The report has segmented the market on the basis of region, product, cell type, technology, application and end user.

Breakup by Product:

  •  Instruments
  • Consumables

Breakup by Cell Type:

  • Human Cells
  • Animal Cells

Breakup by Technology:

  • Centrifugation-based Cell Separation
  • Surface marker-based Cell Separation
  • Filtration-based Cell Separation

Breakup by Application:

  • Oncology Research
  • Neuroscience Research
  • Stem Cell Research
  • Microbiology
  • Immunology Research
  • Others

Breakup by End User:

  • Research Laboratories and Institute
  • Biotechnology and Biopharmaceutical Companies
  • Cell Banks

Breakup by Region:

  • North America: (United States, Canada)
  • Asia Pacific: (China, Japan,India, South Korea, Australia, Indonesia, Others)
  • Europe: (Germany, France,United Kingdom, Italy, Spain, Russia, Others)
  • Latin America: (Brazil, Mexico, Others)
  • Middle East and Africa

If you want latest primary and secondary data (2022-2027) with Cost Module, Business Strategy, Distribution Channel, etc. Click request free sample report, published report will be delivered to you in PDF format via email within 24 to 48 hours of receiving full payment.

Key highlights of the report:

  • Market Performance (2016-2021)
  • Market Outlook (2022- 2027)
  • Porter’s Five Forces Analysis
  • Market Drivers and Success Factors
  • SWOT Analysis
  • Value Chain
  • Comprehensive Mapping of the Competitive Landscape

If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

IMARC Services Private Limited.
30 N Gould St Ste R
Sheridan, WY 82801 USA – Wyoming
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800

Entrepreneurs

The WittyFeed Triumph: Vinay Singhal, Parveen Singhal, and Shashank Vaishnav’s Journey to Content Dominance

Avatar photo

Published

on

Vinay Singhal, Parveen Singhal, and Shashank Vaishnav have created a stunning success story with WittyFeed in the digital world, where content is king. Rising from the ashes of failed businesses, these computer experts changed course and built the second-largest content platform globally, only surpassed by BuzzFeed. This piece explores the story of these visionary founders and how WittyFeed rose to prominence in the content industry.

In 2013, faced with the setbacks of two unsuccessful ventures, Vinay, Parveen, and Shashank decided to stay the course. Ditching Evrystry.com and FollowMe247, they envisioned a content platform that catered to the needs of content creators, distributors, and consumers. This vision materialized in September 2014 with the launch of WittyFeed—a platform that rapidly ascended the ranks to become the third-most visited website in the Indian entertainment category.

For Vinay Singhal, WittyFeed is not just a content platform; it’s a technology play. Leveraging robust technology and analytics, WittyFeed ensures its content goes viral by intricately guiding content selection, creation, distribution, and monetization. Real-time data analysis and insights into user behavior empower thousands of influencers to disseminate content, making WittyFeed a formidable player in the global content arena.

WittyFeed’s strategic foresight extends to its strong network of influencers, positioning the platform years ahead of its competitors. Recognizing influencers as the distributors in the digital world, WittyFeed created Viral9.com—an influencer platform with around 15,000 influencers. These influencers, with millions of followers, redirect traffic to WittyFeed, creating a symbiotic relationship that propels the platform’s reach.

WittyFeed’s impact transcends borders, with a presence in Spain, the US, and the UK, while rapidly gaining traction in India. The platform boasts over 100 million sessions and 60 million unique visitors monthly, generating revenues of ₹30 crore in FY17. Programmatic advertising forms a significant revenue stream, complemented by sponsored content collaborations with around 70 brands, including Uber, Coca-Cola, and Zee Studios. By endearing itself to brands, WittyFeed aims to derive 40 percent of its revenues from brand partnerships.

While WittyFeed has thrived, the platform remains vigilant about potential challenges, especially as Facebook’s algorithms evolve. Vinay emphasizes the importance of steering clear of click-bait and focusing on quality content to maintain a symbiotic relationship with Facebook. Future strategies include the integration of video content, fostering collaborations with mobile apps, and seeking a series A funding round for expansion.

The success of WittyFeed lies in the synergy of its founders—Parveen Singhal, Vinay Singhal, and Shashank Vaishnav. Parveen, the Chief Content Officer, envisions video content as the next growth frontier. Vinay, with a knack for building solutions, steers the technology-driven aspects, while Shashank, the Chief Technology Officer, brings real-time data analytics to the forefront.

As WittyFeed charts a course toward greater heights, its founders remain attuned to the evolving nature of digital consumption. Vinay Singhal encapsulates the essence of their journey, emphasizing the imperative of staying at the forefront of change. The triumvirate’s journey from the brink of failure to commanding one of the world’s largest content platforms is not just a success story; it’s a testament to resilience, innovation, and the power of strategic vision. In an ever-evolving digital landscape, WittyFeed and its founders stand poised for continued impact and influence.

Continue Reading

Entrepreneurs

Rahul Narang and Saurabh Arora: Architects of Healthcare Transformation at Lybrate

Avatar photo

Published

on

Rahul Narang and Saurabh Arora‘s combined genius is evident in the rapidly changing field of healthcare innovation as they lead Lybrate, a ground-breaking online platform for medical consultations. The story takes place against the backdrop of Saurabh Arora, who attended Columbia Business School and IIT Delhi before purposefully changing his course. 2014 saw Arora leave his position as a data scientist at Facebook in Silicon Valley in order to pursue his homegrown business goals. This crucial choice launched Lybrate in 2015, a platform that has the potential to completely transform patient-doctor relations.

Arora’s vision for Lybrate germinated during a visit to India, where he keenly observed the challenges posed by self-medication in rural areas and the inconveniences faced by urban denizens. Fueled by a determination to bridge these gaps, Arora enlisted the expertise of his former colleague and friend, Rahul Narang, who assumed the role of co-founder and chief technology officer at Lybrate.

The platform, operating as an online out-patient department (OPD), strategically deploys technology to enhance the accessibility of quality healthcare across India. Arora’s mission was to seamlessly connect patients and doctors, transcending geographical constraints. In less than three years, Lybrate has garnered over 1 lakh registered doctors, facilitating upwards of 6 million interactions monthly. These interactions span doctor searches, health queries, and appointments for consultations and lab tests.

The triumph of Lybrate can be attributed to its innovative approach and meticulous planning. Arora underscores the critical importance of aligning the product with the workflow of doctors, fostering positive word-of-mouth recommendations. The nascent stages involved securing funding, with Gokul Rajaram, a luminary in developing Google’s AdSense network, playing a pivotal role. Lybrate secured a seed round of $1.23 million from Nexus Venture Partners, Rajaram, and independent investor Vispi Daver in August 2014. A subsequent funding round in July 2015 saw a commitment of $10.2 million from Tiger Global, Nexus Venture Partners, and Ratan Tata, propelling Lybrate’s mission to new heights.

The healthcare landscape in India presents a formidable challenge, marked by a concerning doctor-patient ratio of 1:1,700, as highlighted by a joint report from KPMG and Ficci. What sets Lybrate apart is its unwavering focus on alleviating the doctor shortage. The platform’s workflow begins with anonymous health-related queries from patients, evolving into online or offline consultations as comfort levels with the doctors on the platform grow.

Lybrate’s distinctive patient engagement model places the patient at the center, offering access to a comprehensive spectrum of healthcare services. This strategic differentiator positions Lybrate favorably against Practo, its major competitor, which primarily functions as a doctor discovery platform. While Practo concentrates on appointment scheduling, Lybrate is committed to transforming the patient-doctor interaction and propelling it into the digital realm.

Despite the myriad challenges, Lybrate has achieved a commendable turnover of over ₹22.45 crore in FY15-16, with aspirations to reach ₹25 crore in the current fiscal year. The platform boasts various revenue streams, including ‘Lybrate Consult,’ allowing users to consult preferred doctors for a fee. ‘Lybrate Lab+’ and ‘Lybrate Cube’ contribute significantly to the company’s revenue by facilitating lab tests and providing tools for doctors to enhance their online presence.

As the health tech industry witnesses an influx of competitors, Lybrate’s early entry into the fray positions it as a frontrunner. However, challenges persist, and success in this dynamic landscape hinges on delivering a substantial value proposition for both patients and doctors. The journey of Rahul Narang and Saurabh Arora with Lybrate symbolizes a commitment to quality and innovation, marking the advent of a new era in online healthcare solutions.

Continue Reading

Entrepreneurs

Abhishek Shah: Revolutionizing Diabetes Care Through Digital Therapeutics

Avatar photo

Published

on

Abhishek Shah, the 34-year-old CEO of Mumbai-based Wellthy Therapeutics, stands out as an innovator in a world where chronic illnesses like type 2 diabetes are becoming more prevalent. With its AI-powered smartphone app that provides a customised health coach experience, Wellthy Therapeutics aims to revolutionise the treatment of type 2 diabetes. The journey of Abhishek Shah, the founding of Wellthy, and the significant influence it has had on patients such as Smruti Daru are all covered in this article.

Abhishek Shah’s foray into healthcare entrepreneurship was inspired by personal experiences. Growing up in a family of healthcare entrepreneurs, with parents diagnosed with chronic diseases, Shah witnessed the challenges of managing conditions like hypertension and diabetes. This exposure laid the foundation for Wellthy Therapeutics, founded in 2015 with the vision of leveraging technology for behavioral change in healthcare.

Wellthy Therapeutics’ mobile app serves as a personal health coach, utilizing AI to analyze patient data and habits. The app provides continuous guidance and motivation for adopting healthier lifestyle choices, crucial for managing type 2 diabetes. For individuals like Smruti Daru, the app has been transformative, helping her achieve significant improvements in glycated haemoglobin levels and weight within a short period.

At the core of Wellthy’s philosophy is an outcome-focused approach. Abhishek Shah emphasizes the importance of improving patient outcomes by addressing behavioral changes. The app guides patients through their daily routines, encouraging them to log diet, monitor sugar levels, track weight, and adhere to exercise routines. This focus on quantifiable outcomes sets Wellthy apart in the realm of digital therapeutics.

Wellthy Therapeutics has garnered recognition and endorsements from major organizations. Partnering with the Research Society for the Study of Diabetes in India (RSSDI) in 2016, Wellthy became a prescribed application for doctors. The company presented positive clinical outcomes at an American Diabetes Association conference, establishing itself as the first South Asian digital therapeutics firm with such achievements. Understanding the unique cultural nuances of India and Asia, Wellthy tailored its app to cater specifically to the genetic makeup, behavior, and values prevalent in the region. Recognizing that two-thirds of the world’s diabetics reside in Asia, Wellthy’s regional focus positions it strategically in the fight against diabetes.

Abhishek Shah’s commitment to improving healthcare outcomes is reflected in Wellthy’s self-funded growth. Investing around ₹2.9 crore into the venture, Shah prioritized creating a product that genuinely benefited patients. Wellthy’s expansion involves unique partnerships with hospitals, doctors, patients, and insurance companies, laying the groundwork for future growth. With plans to go live in the Middle East later this year, Wellthy envisions achieving a full-fledged presence in Asia within four to five years. The company’s trajectory aligns with its mission to redefine diabetes care through innovative technology and a patient-centric approach.

For Abhishek Shah, the journey of building Wellthy intertwines with the personal milestone of becoming a father. This balancing act, navigating the realms of first-generation entrepreneurship and first-time fatherhood, shattered perceived limitations and unlocked newfound capabilities. Shah’s dedication to his vision has not only transformed his life but has become a source of empowerment for individuals managing diabetes.

Continue Reading

Trending